Replimune Group Inc (REPL) Stock Price, Quote & News

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 222 9600

Website: www.replimune.com

Address:

500 Unicorn Park Drive, Suite 303, Woburn, United States

LineBacker04 Oct. 25 at 12:39 AM

$CAPR Part-3 4. And finally...PUL 2.0 did pass the initial futility analysis - which means the study monitors were noticing a difference at 3 months - which is expected to broaden at 12 months. The other aspect is what happens if PUL 2.0 is a marginal miss? For me in this situation, the expectation is that they will be able to respond to the CRL with LVEF "additional data" and restart the BLA. It will result in a narrower label, but it will likely lead to an approval. From what I'm told, there's language in the type-A meeting minutes talking about "regulatory flexibility" - and I expect this to show up just like it did for $REPL earlier this month. The reason for this is not just a change of heart for Dr. Vinay Prasad - its a situation where he's feeling the pressure from multiple sources and he needs to demonstrate this "flexibility" just to stay on the job. I'm also told that in this scenario - $CAPR will not only PR the results, but till also PR their intent to respond to the CRL.

5 · Reply

Smellmahass Oct. 24 at 10:35 PM

$AQST This and $REPL My medium long term. Pdufas always run up. Almost risk free investement. As the catalysts is the pdufa which usually come at the last week.

0 · Reply

BiotechDrTrader Oct. 24 at 10:09 PM

$REPL for anyone saying adcom would be a bad thing for replimune, ur smoking it, given the massive support from oncologists any adcom would support approval for sure and be a positive

2 · Reply

Julie25 Oct. 24 at 9:42 PM

$REPL Not going to be approved. AdComm will reject it before FDA does. RUN.

0 · Reply

BiotechDrTrader Oct. 24 at 8:03 PM

$REPL What happened to all the shorts? They all quiet now that price has stabilized - I continue to think that now that vinay prasad has had his near death experience being fired and coming back, he's decided that it's not worth his political career to reject good drugs like replimune for stupid reasons, like wanting a non-ethical control arm. He wanted to treat checkpoint progressors with more checkpoints lol, when all the literature says its pointless. Oh and after the FDA already agreed the study design was fine previously. I think he will quietly approve REPL this time around and move on with his life.

2 · Reply

UnicornProfits Oct. 24 at 7:57 PM

If you missed those runs on $ARTV $REPL $NTRP $CIIT Don't miss ticker CMCT !! CMCT has only 728k shares float and is the next squeeze! Looks like shorts got trapped below and now CMCT is squeezing up!!

0 · Reply

Main_Street_Risks Oct. 24 at 7:24 PM

$REPL Thoughts on resubmission. They come out of meeting and say they have not determined path forward for accelerated approval, then fast forward couple weeks and we have an accepted BLA and Pdufa of April 10th? So they took about 3 weeks to make resubmission (resubmitted Oct 10). What did they decide between Sep and Oct 10th? Likely to take the higher risk/ fastest option which includes addressing the FDA comments (with new data cuts/analysis) but not fully addressing the issue (no new trial). What should be clear is this path is not a clear path to accelerated approval or they would have said so. The best they did was say the FDA considers it a complete response…which actually just means they answered every question, inherent to the BLA acceptance. This is likely the only decent option for them. Create hope. Raise more funds and buy time. There really isn’t a legitimate alternative if FDA is willing to take another look without a new trial.

1 · Reply

Smellmahass Oct. 24 at 10:43 AM

$REPL Whats likelihood this will get an adcom comittee?

2 · Reply

BiotechDrTrader Oct. 23 at 7:02 PM

$REPL Just a reminder that the majority of oncologists world wide were expecting REPL to be approved the first time based on the exceptional data, and now vinay prasad has the chance to fix his error while saving face by pointing to additional data submitted by the company. I bet it gets approved several months prior to PDUFA since FDA already familiar with the submission ... :) https://www.linkedin.com/posts/kevin-harrington-013b4b3b_letter-to-office-of-the-commissioner-usfda-activity-7356063520137875457-6DGa/?utm_source=share&utm_medium=member_ios&rcm=ACoAAC2z7UcBrMA01Zg-q3xZNgm4J15ou08OD2Y

2 · Reply

Bonanza2252003 Oct. 23 at 6:17 PM

$REPL Don’t fight it baggies . It’s just not going to get worse tomorrow 🤣

0 · Reply

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 19, 2025, 8:00 AM EDT - 6 days ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Sep 21, 2025, 7:40 AM EDT - 4 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

Replimune Provides Update Following Type A Meeting with FDA

Sep 13, 2025, 10:10 AM EDT - 6 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 5, 2025, 6:54 PM EDT - 7 weeks ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 7 weeks ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Replimune Announces Type A Meeting Scheduled with FDA

Aug 13, 2025, 4:39 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 3:26 PM EDT - 2 months ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 7, 2025, 10:08 AM EDT - 2 months ago

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 4, 2025, 12:43 PM EDT - 2 months ago

Why Is Replimune Stock Trading Lower On Monday?

Aug 1, 2025, 10:51 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Jul 30, 2025, 8:36 AM EDT - 3 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 28, 2025, 8:36 AM EDT - 3 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 25, 2025, 5:04 PM EDT - 3 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 24, 2025, 8:07 AM EDT - 3 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 22, 2025, 2:56 PM EDT - 3 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 11:03 AM EDT - 3 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 11, 2025, 4:01 PM EDT - 3 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2025, 10:00 AM EDT - 5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2025, 8:00 AM EDT - 5 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 22, 2025, 11:19 AM EDT - 5 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 7:00 AM EDT - 5 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:00 AM EDT - 5 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 9, 2025, 4:01 PM EDT - 6 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 5:00 AM EDT - 6 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Apr 28, 2025, 3:26 PM EDT - 6 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Feb 12, 2025, 4:21 PM EST - 9 months ago

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 8:00 AM EST - 9 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Dec 23, 2024, 8:00 AM EST - 10 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LineBacker04 Oct. 25 at 12:39 AM

5 · Reply

Smellmahass Oct. 24 at 10:35 PM

$AQST This and $REPL My medium long term. Pdufas always run up. Almost risk free investement. As the catalysts is the pdufa which usually come at the last week.

0 · Reply

BiotechDrTrader Oct. 24 at 10:09 PM

$REPL for anyone saying adcom would be a bad thing for replimune, ur smoking it, given the massive support from oncologists any adcom would support approval for sure and be a positive

2 · Reply

Julie25 Oct. 24 at 9:42 PM

$REPL Not going to be approved. AdComm will reject it before FDA does. RUN.

0 · Reply

BiotechDrTrader Oct. 24 at 8:03 PM

2 · Reply

UnicornProfits Oct. 24 at 7:57 PM

0 · Reply

Main_Street_Risks Oct. 24 at 7:24 PM

1 · Reply

Smellmahass Oct. 24 at 10:43 AM

$REPL Whats likelihood this will get an adcom comittee?

2 · Reply

BiotechDrTrader Oct. 23 at 7:02 PM

2 · Reply

Bonanza2252003 Oct. 23 at 6:17 PM

$REPL Don’t fight it baggies . It’s just not going to get worse tomorrow 🤣

0 · Reply

BiotechDrTrader Oct. 23 at 5:59 PM

$REPL $REPL it’s so annoying how X is flooded with spam for replimune, those bots are the worst…

0 · Reply

Bonanza2252003 Oct. 23 at 2:51 PM

$REPL Looks like we caught some more bagholders today 🤣

0 · Reply

ProfessorGamma Oct. 22 at 11:01 PM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $MLTX $COKE $REPL $MNTS Watchlist,

0 · Reply

BiotechDrTrader Oct. 22 at 8:14 PM

$REPL awww are the shorts crying today? Trying to cover? sad to see

1 · Reply

Alidrisi Oct. 22 at 8:05 PM

$REPL

0 · Reply

BiotechDrTrader Oct. 22 at 7:48 PM

$REPL Just FYI, FDA said the additional data and analyses included in the most recent re-submission addresses the CRL (the CRL was stupid in the first place, asking for a control arm when it would be unethical to do so and was already agreed on earlier that it wasn't needed), so now they will obviously adjudicate on it, but I have a good feeling this time around it will be approved. Vinay Prasad saw his life flash before his eyes when the sarepta patient outcry caused him to get ousted and then brought back in, and he's noticeably backed off from sarepta. He's also not saying anything negative about the tylenol / autism idiocy coming from the current administration. He will choose the easier path and approve REPL this time around. ALSO, FDA approvals can happen months prior to PDUFA dates, and theres been a trend of early approvals recently. Since they are already familiar with the data, I think theres a good chance FDA approval happens earlier than the stated PDUFA date. Bullish!

2 · Reply

Bonanza2252003 Oct. 22 at 5:29 PM

$REPL Just stopping by to remind you , sub $5 by Friday 🤣💪

2 · Reply

MKRReformed Oct. 22 at 4:33 PM

$REPL $VKTX 1) there actually isn’t any analysis, but rather bragging about calls I already got right. 2) I am almost assuredly a better trader than you, as I am 99%+ of people as evidenced by easily crushing the market for three straight years since going full time, being in the top 5000 on tip ranks, and literally getting audited due to an abnormally high RoI. Time is in Buenos Aires time (where I’ve functionally retired in my early 30s) and all Index %s are accurate within the past day or two due to there being update lag on the actual websites It’s ok to be insecure, especially if you’re losing money on both these plays that I’ve had very good rois on shorting, but it’s really not my responsibility to coddle your ignorance. I’m well within the top 1% of traders in the world, all while maintaining very tight risk management. Gain some self awareness and some money scrub

1 · Reply

biolover Oct. 22 at 3:51 PM

$REPL $VKTX idiot analysis

0 · Reply

MKRReformed Oct. 22 at 3:30 PM

$REPL 9 puts now up 200% if held, common share short up 22% from $10. Bear side paying big $VKTX 32.5p now up 85% from entry. Cashing out and switching to 30p in .70s To survive this type of market you have to play both ways

2 · Reply

Maddmike Oct. 22 at 2:56 PM

$REPL

0 · Reply

Gj64 Oct. 22 at 2:28 PM

$REPL https://www.stocktitan.net/news/GRTX/galera-therapeutics-announces-acquisition-of-dismutase-mimetics-8pulrnbo7s22.html

0 · Reply

Market Cap	657.23M
Revenue (ttm)	0.00
Net Income (ttm)	-247.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.14

Volume	2,188,800
Avg Vol	5,830,136
Day's Range	N/A - N/A
Shares Out	78.06M
Stochastic %K	75%
Beta	0.42
Analysts	Sell
Price Target	$10.43